844499-00-9

Usage

Uses

Used in Pharmaceutical Research:
3-(CHLOROMETHYL)-5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOLE is used as a compound in pharmaceutical research for its potential antimicrobial, antifungal, and anticancer properties. Its unique structure and chemical reactivity allow it to interact with biological targets, making it valuable for drug discovery and development.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 3-(CHLOROMETHYL)-5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOLE is utilized as a building block for the synthesis of new compounds with therapeutic potential. Its chlorine and fluorine substituents contribute to its reactivity and the possibility of creating derivatives with enhanced biological activities.
Used in Drug Discovery:
3-(CHLOROMETHYL)-5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOLE is employed in drug discovery as a lead compound for the development of new therapeutic agents. Its potential biological activities and chemical properties make it an important compound for further investigation and potential applications in treating various diseases and conditions.

InChI:InChI=1/C9H6ClFN2O/c10-5-8-12-9(14-13-8)6-3-1-2-4-7(6)11/h1-4H,5H2

Upstream product

• 3272-96-6 2-chloro-N-hydroxyethanimidamide 
• 393-52-2 2-Fluorobenzoyl chloride 
• 844498-86-8 C₉H₈ClFN₂O₂ 

Relevant academic research and scientific papers

ALKALOID AMINOESTER DERIVATIVES AND MEDICINAL COMPOSITION THEREOF

The present invention relates to alkaloid aminoester derivatives acting as muscarinic receptor antagonists, processes for their preparation, compositions comprising them and therapeutic uses thereof.

New GABA-modulating 1,2,4-oxadiazole derivatives and their anticonvulsant activity

A series of 3- and 5-aryl-1,2,4-oxadiazole derivatives were prepared and tested for anticonvulsant activity in a variety of models. These 1,2,4-oxadiazoles exhibit considerable activity in both pentylenetetrazole (PTZ) and maximal electroshock seizure (MES) models. Compound 10 was protective in the PTZ model in rats with an oral ED50 of 25.5 mg/kg and in the MES model in rats with an oral ED50 of 14.6 mg/kg. Neurotoxicity (rotarod) was observed with an ED50 of 335 mg/kg. We found several oxadiazoles that acted as selective GABA potentiating compounds with no interaction to the benzodiazepine binding site.

The discovery of a selective, high affinity A2B adenosine receptor antagonist for the potential treatment of asthma

Adenosine has been suggested to play a role in asthma, possibly via activation of A2B adenosine receptors on mast cells and other pulmonary cells. We describe our initial efforts to discover a xanthine based selective A2B AdoR antagonist that resulted in the discovery of CVT-5440, a high affinity A2B AdoR antagonist with good selectivity (A2B AdoR Ki = 50 nM, selectivity A1 > 200: A2A > 200: A3 > 167).